Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Explore this paper's citation graph
Summary
The aim of this review is to summarise the function and effect of established and emerging costimulatory domains and their combinations within CAR T cells.
- Type
- review
- Published
- 2019-05-11
- Cited by
- 282
- References
- 78
- Access
- Open access
- OpenAlex
- https://openalex.org/W2944669426
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:159037858
Keywords
Chimeric antigen receptor, CD28, T cell, CD19, Biology
References
- Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
- Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition
- 4-1BB Ligand-Mediated Costimulation of Human T Cells Induces CD4 and CD8 T Cell Expansion, Cytokine Production, and the Development of Cytolytic Effector Function1
- Immune Responses in 4-1BB (CD137)-Deficient Mice1
- ICOS Ligation Recruits the p50α PI3K Regulatory Subunit to the Immunological Synapse1
- Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.
- A Costimulatory Function for T Cell CD401
- 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors
- 4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1
- Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions.
- Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies
- Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
- A new analysis of allogeneic interactions.
- Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
- In vivo persistence, tumor localization and anti-tumor activity of CAR engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
- CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.
- A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
- Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging.
- CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
Cited by
- Cancer Cell Signaling: Methods and Protocols
- Chimeric antigen receptor T cell persistence and memory cell formation
- The Promise of Chimeric Antigen Receptor (CAR) T Cell Therapy in Multiple Myeloma
- Current Perspectives in Cancer Immunotherapy
- Commentary on: Cordeiro, A, Bezerra, ED, Hirayama, AV, Hill, JA, Wu, QV, Voutsinas, J, Sorror, ML, Turtle, CJ, Maloney, DG, and Bar, M. Biology of Blood and Marrow Transplantion, August 13, 2019).
- MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)—Current Treatment Options. Is There a Role for CAR-T Cell Therapy?
- Enterotoxins can support CAR T cells against solid tumors
- T Cell Reprogramming Against Cancer
- Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies
- Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia
- Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
- Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma.
- Chimeric antigen receptor T‐cell therapies: Optimising the dose
- 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling
- Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
- Clinical Practice: Chimeric antigen receptor (CAR) T cells – a major breakthrough in the battle against cancer
- CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells
- HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo
- CARs: Beyond T Cells and T Cell-Derived Signaling Domains
- InVivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes.
Related papers
- 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors
- Tinkering in the garage — tuning CARs for safety
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- Distribution Measurements of Chimeric Antigen Receptor-Modified T Cells Against CD19
- B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?
- Anti-cd19-car-transduced-t-cells/chimeric-antigen-receptor-t-cell-therapeutics-shanghai-unicar-therapy-bio-medicine-technology
- Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions
- Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
- Validation of Pre-Treatment Modified Easix Score As a Predictor of Cytokine Release Syndrome Related to Anti CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
- Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19